|drug106||ARFC mask Wiki||0.71|
|drug3499||Toraymyxin PMX-20R (PMX Cartridge) Wiki||0.71|
|drug246||Angiotensin II Wiki||0.50|
There are 2 clinical trials
Prospective, observational, clinical investigation of PMX cartridge use in COVID 19 patients with septic shock
Septic shock continues to exert a large economic burden around the world. Several developments have occurred that lead to the current study. First, angiotensin II is the newest FDA approved vasopressor agent indicated for use in vasodilatory shock. Several subgroups from the approval trial have indicated that angiotensin II may confer a survival benefit in certain conditions, including those patients requiring continuous renal replacement therapy, those with altered angiotensin I: angiotensin II ratios, and most recently, those with elevated renin levels (which may serve as a surrogate for dysfunctional angiotensin 1: angiotensin II ratios). This open-label, sequential period pilot study will evaluate angiotensin II and biomarker response (renin) in the treatment of septic shock.
Description: Plasma renin levels will be measured from blood collected at baseline, 24 hours, and at shock resolution. Additionally, a 3-hour measurement will be included in the angiotensin II arm.Measure: Change in Plasma Renin Levels Time: Until shock resolution, up to 14 days (at baseline, 3 hours, 24 hours, and shock resolution, up to 14 days)
Description: Cystatin C, NGAL will be measured from blood collected at baseline, 24 hours, and at shock resolution.Measure: Change in Renal Biomarkers Time: Until shock resolution, up to 14 days (at baseline, 24 hours, and shock resolution, up to 14 days)
Description: Time from enrollment to discontinuation of catecholaminesMeasure: Time to discontinuation of catecholamines Time: Until shock resolution, up to 14 days
Description: Number of days in the intensive care unit (ICU).Measure: ICU Length of Stay Time: From enrollment to ICU discharge, up to 28 days following enrollment
Description: Assessment of all-cause mortality within hospital admissionMeasure: In-hospital mortality Time: Up to 3 months following enrollment
Description: Days free of renal replacement therapy from enrollment up to day 28Measure: Renal replacement therapy-free days Time: Within 28 days of enrollment
Description: Incidence of venous thromboembolism, arrhythmia, extremity hypoperfusion, delirium, new ischemic event, new infectionMeasure: Safety outcomes Time: Up to 72 hours following shock resolution, no longer than 17 days from enrollment
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports